Compare Biogen Inc (BIIB) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Gartner Inc — how do they compare? Biogen Inc trades at $195.51 (market cap $28.34B), while Gartner Inc trades at $134.67 (market cap $8.90B). The key difference: Biogen Inc is far larger — about 3.2× Gartner Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | IT | |
|---|---|---|
Market Cap | $28.34B | $8.90B |
Sector | Health | Technology |
52-Week High | $216.63 | $363.58 |
52-Week Low | $122.68 | $125.68 |
Enterprise Value | $30.62B | $10.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Gartner (IT) trades at $141.31, up 6.06% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 68.99% gross margin and 11.44% net margin, though 2025 net income declined to $729 million. Recent news highlights its leadership in AI platforms, but an ongoing legal investigation poses a near-term risk.
Outlook remains positive with a consensus price target of $157.60, suggesting 11.5% upside. Key opportunities include sustained demand for IT research and consulting, while risks involve heightened competition and the February 2025 legal probe. Institutional sentiment is mixed with 27.8% buy ratings amid cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
